On July 6, Keymed Biosciences rose 5.16% in regular trading, trading at 85.0 HKD/share, with turnover of approximately 115 million HKD, extending its recent strong momentum.

On the news front, multiple positive catalysts are converging. The company recently received CDE clinical trial acceptance for two Class 1 innovative drugs on the same day, accelerating its pipeline advancement. Meanwhile, China's National Healthcare Security Administration published 557 drugs passing basic medical insurance directory initial review and 54 drugs passing commercial insurance innovative drug directory initial review. The dual-directory negotiation mechanism combining public medical insurance and commercial insurance has entered a substantive phase, with an 8-year price protection mechanism simultaneously implemented. Market expectations for volume growth of high-clinical-value innovative drugs continue to strengthen.

Within the Biotechnology sector, peers also posted gains: REMEGEN up 3.64%, INNOVENT BIO up 3.36%, 3SBIO up 3.32%, SKB BIO up 1.6%, and AKESO up 1.07%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)